|Click here for details on how to download this file |
Where can you turn for help in preventing MENB?
Serogroup B has become the most common invasive meningococcal disease (IMD) serogroup to affect Canadians (2011).
Percentage of reported IMD cases by age and serogroup, Canada (2007-2011)
AMONG INFANTS <1 year of age
AMONG CHILDREN 1-4 years of age
AMONG ADOLESCENTS 15-19 years of age
The first and only vaccine indicated for active immunization against invasive meningococcal disease caused by serogroup B strains.
BEXSERO is indicated for active immunization of individuals from 2 months through 17 years old against invasive disease caused by N. meningitidis serogroup B strains.
Multicomponent Meningococcal B Vaccine (recombinant, adsorbed)
Be informed. Be immunized.
Other ads from this campaign
Country/Market: Canada, North America
Target: Healthcare Professional (HCP)
Tagline: Be informed. Be immunized.
CMAJ-JAMC - May 19, 2015
See more Bexsero ads
|Rate this file (No vote yet)|
|Download:||Available for logged-in users with full-size access enabled.|
|Date added:||May 24, 2015|
|Dimensions:||3684 x 5000 pixels|
|My Collection:||Add to collection|